 | |
|
Diagnosis and pharmacological management of Parkinson's disease
— summary of SIGN guidelines |
| Author(s) | D G Grosset, G J A Macphee, M Nairn |
| Corporate Author | Guidelines Development Group, Scottish Intercollegiate Guidelines Network (SIGN) |
| Journal title | British Medical Journal, vol 340, no 7739, 23 January 2010 |
| Pages | pp 206-209 |
| Source | www.bmj.com doi: 10.1136/bmj.b5614 |
| Keywords | Parkinson's disease ; Diagnosis ; Drugs ; Standards of provision ; Scotland. |
| Annotation | Parkinson's disease (PD) is a common neurodegenerative disease diagnosed in 1% of people aged over 65. It has a considerable impact on patients and their families as well as healthcare and social care systems. With an ageing population, the number of cases in Scotland may increase by 30% in the next 25 years. Accurate diagnosis can be difficult, particularly at first presentation. As the disease progresses, treatment with complex combinations of drugs often becomes the norm. This article summarises the recommendations from the Scottish Intercollegiate Guidelines Network (SIGN) of the diagnosis and drug management of Parkinson's disease. (RH). |
| Accession Number | CPA-100203203 A |
| Classmark | CR6: LK7: LLD: 583: 9A * |
Data © Centre for Policy on Ageing |
|
| ...from the Ageinfo database published by Centre for Policy on Ageing. |